Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

OGEN vs PTN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PTN Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–3 Matrix Metrics)

PTN Overall Winner 6-Pillar Tally: OGEN 1 – 4 PTN (1 Tie) Matrix Metrics: OGEN 3 – 7 PTN

As of Nov 16, 2026, Palatin Technologies, Inc. (PTN) is the stronger overall head-to-head candidate over Oragenics Inc. (OGEN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). OGEN carries a Unified Composite Score of 38.8/100 (SELL) at $0.20 (N/M Forward P/E, 0.0% operating margin), whereas PTN carries 31.5/100 (SELL) at $6.12 (42.9x Forward P/E, -65.7% operating margin).

  • Composite vs. Pillar Nuance: While OGEN currently prints a higher short-term Unified Composite Score (38.8/100 SELL vs. PTN 31.5/100 SELL), PTN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-65.7% vs. 0.0% operating margin) and revenue trajectory (-80.1% vs. -91.3% YoY).
  • Defensive Composite Rating Caution: Although PTN compares more favorably head-to-head, both OGEN (38.8/100 SELL) and PTN (31.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: OGEN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 14.1); meanwhile PTN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OGEN vs PTN
OGEN NYSE American
Oragenics Inc.
Pharmaceutical Preparations
$0.20
-1.49% 1D
Market Cap $906,903
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.19β · 153% Vol
Unified Composite Score
38.8 / 100 SELL
Tech 25.0 Fund 46.0 Flow 50.0 Mom 75.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.5%), weak momentum, RSI 14
RSI-14: 14.1 · SMA20: $0.36 · SMA50: $0.43
PTN US Equity Head-to-Head Winner
Palatin Technologies, Inc.
Pharmaceutical Preparations
$6.12
-1.69% 1D
Market Cap $11.1M
TTM Revenue $13M
Forward P/E 42.9x
Beta / 30D Vol 0.87β · 106% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 15.0 Fund 30.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.5%), weak momentum, RSI 45
RSI-14: 44.9 · SMA20: $5.72 · SMA50: $8.07

6-Pillar Scorecard Institutional Category Breakdown (OGEN 1 – 4 PTN)

Columns: Metric · OGEN · PTN
1. Valuation Multiples PTN
Forward P/E N/M 42.9x
Trailing P/E N/M 42.9x
PEG Ratio N/M 1.62x
EV / Revenue N/M 0.1x
2. Growth & Scale PTN
Revenue Growth (YoY) -91.3% -80.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $13M
Market Cap $906,903 $11.1M
3. Profitability & Quality OGEN
Gross Margin N/A 6.2%
Operating Margin 0.0% -65.7%
Net Profit Margin 0.0% -63.5%
Return on Equity (ROE) -1307.1% -877.5%
4. Balance Sheet & Cash Flow PTN
Cash Generation (TTM) N/A -$15M
Cash Flow Margin N/A -113.6%
Net Cash / Leverage $1.94 Book/Sh · -1307.1% ROE $9.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat PTN
OpEx & R&D Intensity N/A 71.9% of Rev ($9.5M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OGEN (3) vs PTN (7)
Institutional Metric OGEN PTN Criterion Row Edge
Market Capitalization
Scale
$906,903 $11.1M Larger Scale PTN
Trailing P/E Ratio
Valuation
N/M 42.9x Lower Multiple PTN
Forward P/E Ratio
Valuation
N/M 42.9x Lower Multiple PTN
Revenue Growth (YoY)
Growth
-91.3% -80.1% Higher Growth PTN
Operating Margin (TTM)
Profitability
0.0% -65.7% Higher Margin OGEN
Net Profit Margin
Profitability
0.0% -63.5% Higher Margin OGEN
Return on Equity (ROE)
Capital Efficiency
-1307.1% -877.5% Higher ROE PTN
52-Week Range Position
Momentum
3% ($0–$1) 6% ($5–$31) Stronger Trend PTN
Beta / 30D Volatility
Risk Regime
1.19β · 153% Vol 0.87β · 106% Vol Lower Realized Risk PTN
Unified Institutional Score
Composite Signal
38.8 / 100 (SELL) 31.5 / 100 (SELL) Higher Composite OGEN
Trailing 12M Revenue (USD)
Operating Scale
N/A $13M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 6.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.62x PEG · 0.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($1.94 Book/Sh · -1307.1% ROE) -$15M ($9.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PTN +56.21 pp
OGEN: -54.47% · PTN: +1.74%
3M Horizon PTN +22.02 pp
OGEN: -63.74% · PTN: -41.72%
6M Horizon PTN +5.52 pp
OGEN: -65.33% · PTN: -59.81%
1Y Horizon PTN +39.34 pp
OGEN: -82.63% · PTN: -43.29%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period OGEN Revenue PTN Revenue OGEN Op. Margin PTN Op. Margin Margin Leader
FY2018 N/A $70M N/A 38.6% PTN
FY2019 N/A $60M N/A 59.3% PTN
FY2020 N/A $0M N/A -20007.6% PTN
FY2021 $0M N/A -18130.3% N/A OGEN
FY2022 $0M $0M -10964.6% -2491.6% PTN
FY2023 $0M $0M -55519.9% -668.7% PTN
FY2024 N/A $0M N/A -501.0% PTN
FY2026 N/A $10M N/A -65.7% PTN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OGEN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PTN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PTN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OGEN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $906,903 market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PTN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $11.1M market capitalization and -65.7% operating margin.
OpEx & R&D Reinvestment 71.9% of Rev ($9.5M)
90D Engineering Disclosures 0 Published

Investor FAQ OGEN vs PTN Key Questions & Quantitative Answers

As of Nov 16, 2026, Palatin Technologies, Inc. (PTN) is the stronger overall head-to-head candidate over Oragenics Inc. (OGEN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). OGEN carries a Unified Composite Score of 38.8/100 (SELL) at $0.20 (N/M Forward P/E, 0.0% operating margin), whereas PTN carries 31.5/100 (SELL) at $6.12 (42.9x Forward P/E, -65.7% operating margin). Composite vs. Pillar Nuance: While OGEN currently prints a higher short-term Unified Composite Score (38.8/100 SELL vs. PTN 31.5/100 SELL), PTN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-65.7% vs. 0.0% operating margin) and revenue trajectory (-80.1% vs. -91.3% YoY). Defensive Composite Rating Caution: Although PTN compares more favorably head-to-head, both OGEN (38.8/100 SELL) and PTN (31.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: OGEN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 14.1); meanwhile PTN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PTN leads the Growth & Scale pillar: OGEN posts -91.3% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PTN at -80.1% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (6.2% gross margin, -65.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2026), OGEN cumulative revenue shifted N/A while PTN shifted -85.7%. In operating R&D and SG&A reinvestment, OGEN deploys N/A (0 90-day corporate R&D disclosures) versus 71.9% of Rev ($9.5M) (0 disclosures) for PTN.

PTN screens cheaper on headline valuation multiples. OGEN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas PTN trades at 42.9x Forward P/E, 42.9x Trailing P/E, 1.62x PEG, and 0.1x EV/Revenue (-113.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OGEN (-1307.1% ROE) versus PTN (-877.5% ROE) capital efficiency.

In options market volatility and institutional positioning, OGEN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 153% Vol realized risk). By comparison, PTN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.87β · 106% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.